Status:
RECRUITING
Caffeine, CYPA12 and Resistance Exercise
Lead Sponsor:
Alberto Pérez-López
Collaborating Sponsors:
University of Alcala
iSanidad+Herbalife
Conditions:
CYP1A2 Polymorphism
Caffeine and Resistance Exercise
Eligibility:
All Genders
18-35 years
Phase:
NA
Brief Summary
Introduction: Several studies have evaluated and confirmed the ergogenic effect of acute caffeine intake on sports performance, specifically on strength and power performance. However, it remains to b...
Eligibility Criteria
Inclusion
- Age between ≥ 18 and ≤ 35 years.
- Body mass index (BMI) lower than 25 kg/m².
- Physically active subjects (≥150 min/week of moderate exercise).
- Healthy men and women without neurological, cardiometabolic, immunological, or physical conditions that prevent them from performing physical exercise.
- Participants capable of performing the tests.
Exclusion
- History of neuromuscular, cardiac, or diseases that could affect liver or muscle metabolism.
- Use of drugs or other stimulants that interfere with caffeine intake and intestinal absorption during the tests and study.
- Body mass index (BMI) ≥ 25 kg/m².
- Having undergone prolonged periods of forced physical inactivity during the 6 months prior to the study.
- Performing strenuous exercise within 48 hours prior to the tests.
- Failing to replicate the same food intake on the two experimental days.
- Consuming caffeine after 6 PM on the day prior to training or testing.
Key Trial Info
Start Date :
April 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 30 2025
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06610110
Start Date
April 1 2024
End Date
July 30 2025
Last Update
September 24 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Facultad de Medicina y Ciencias de la Salud. Universidad de Alcalá
Alcalá de Henares, Madrid, Spain, 28805
2
Facultad de Medicina y Ciencias de la Salud. Universidad de Alcalá
Alcalá de Henares, Madrid, Spain